Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

By R. Channick, G. Simonneau, O. Sitbon, I. Robbins, A. Frost, V. Tapson, D. Badesch, S. Roux, M. Rainisio, F. Bodin and 1 more. The Lancet, 2001

1,209 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/29246715a522d077f9afa8ab4d6a25bfb8a6de78

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau
2. N. Galiè

Citations in the corpus

• Pulmonary arterial hypertension (2013, background): “echocardiographic and Doppler variables, and time to clinical worsening [107,225-228].”
• Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 (2004, background): “Abnormal laboratory results including decreased haemoglobin concentration and elevated hepatic transaminases, have been reported in previous bosentan trials [ 16 , 18].”